Eventide Asset Management’s Royalty Pharma RPRX Stock Holding History

Eventide Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$77.7M	Buy	1,380,261 +67,727	+5%	+$3.53M	1.04%	26
2026 Q1	$62.6M	Buy	1,312,534 +15,708	+1%	+$688K	1.04%	23
2025 Q4	$50.2M	Buy	1,296,826 +380,337	+41%	+$14.5M	0.78%	35
2025 Q3	$32.3M	Sell	916,489 -5,150	-0.6%	-$186K	0.53%	71
2025 Q2	$33.4M	Buy	921,639 +41,830	+5%	+$1.39M	0.59%	60
2025 Q1	$27.4M	Buy	879,809 +56,419	+7%	+$1.79M	0.55%	67
2024 Q4	$21M	Buy	823,390 +50,767	+7%	+$1.35M	0.38%	87
2024 Q3	$21.9M	Buy	772,623 +22,993	+3%	+$637K	0.38%	84
2024 Q2	$19.8M	Buy	749,630 +58,943	+9%	+$1.63M	0.34%	92
2024 Q1	$21M	Buy	690,687 +156,712	+29%	+$4.62M	0.33%	90
2023 Q4	$15M	Sell	533,975 -470,171	-47%	-$12.9M	0.24%	104
2023 Q3	$27.3M	Sell	1,004,146 -35,572	-3%	-$1.06M	0.49%	59
2023 Q2	$32M	Sell	1,039,718 -9,395	-0.9%	-$318K	0.54%	58
2023 Q1	$37.8M	Buy	1,049,113 +300,690	+40%	+$11.1M	0.69%	51
2022 Q4	$29.6M	Buy	+748,423	New	+$31.2M	0.58%	56

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Eventide Asset Management's RPRX Position: Q2 2026 in Review

Eventide Asset Management increased its Royalty Pharma (RPRX) stake by 5.2% in Q2 2026, buying an estimated $3.53M and bringing the position to 1,380,261 shares worth $77.7M. The position accounts for 1.04% of the portfolio, ranked #26.

Eventide Asset Management first reported a position in RPRX in Q4 2022 and has held it in 15 quarters since. 641 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Eventide Asset Management held 1,380,261 shares of Royalty Pharma worth $77.7M as of Q2 2026.
Eventide Asset Management bought 67,727 Royalty Pharma shares in Q2 2026, an estimated $3.53M.
Royalty Pharma made up 1.04% of Eventide Asset Management's portfolio in Q2 2026, its #26 holding.
Eventide Asset Management first reported a position in Royalty Pharma in Q4 2022 and has held it in 15 quarters since.
641 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Eventide Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.